RxDoctor Payments Data

Francisco Tellez, MD

Ophthalmology · Wyomissing, PANPI 1285624684

Payments from drug & device makers

$1,468in general payments, 2019–2025

Across 78 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$508
  • AbbVie$267
  • Kala Pharmaceuticals, Inc.$126
  • Sight Sciences, Inc.$115
  • Bausch & Lomb Americas Inc.$75
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$62
  • plus $315 from 12 others

What the payments were for

  • Food & beverage$1,42897%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,468 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$436,897
Medicare patients
817
Services billed
4,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost165$52,738
VyzultaLatanoprostene Bunod70$28,385
RestasisCyclosporine15$20,573
Alphagan PBrimonidine Tartrate44$16,982
CombiganBrimonidine Tartrate/Timolol26$13,480
RocklatanNetarsudil Mesylat/Latanoprost20$11,931
RhopressaNetarsudil Mesylate24$11,293
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$11,190
Brinzolamide34$8,606
Prednisolone Acetate194$7,625
Brimonidine Tartrate86$6,534
Latanoprost693$6,146
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat254$5,573
Travoprost23$4,902
Timolol Maleate347$4,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$267$103,774250 claims
Bausch & Lomb Americas Inc.Vyzulta$75$28,38570 claims
AlconAzopt, Simbrinza$508$6,95924 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$62$2,21816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →